Search Patents
  • 2019-NCOV (SARS-COV-2) VACCINE
    Publication number: 20240108715
    Abstract: The present invention relates to Coronavirus 2019-nCOV spike protein, polynucleotides encoding said spike protein, antibodies and vaccines for treatment or prevention of 2019-nCOV infection.
    Type: Application
    Filed: February 17, 2021
    Publication date: April 4, 2024
    Inventors: Gaurav GUPTA, Reinhard GLUECK
  • Prefusion coronavirus spike proteins and their use
    Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein
    Patent number: 10017784
    Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: July 10, 2018
    Assignee: ID PHARMA CO., LTD.
    Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
  • Synthetic plasmid DNA vaccine expressing a codon-optimized SARS-COV-2 spike protein
    Patent number: 11607449
    Abstract: A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 ?g of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: March 21, 2023
    Assignee: King Abdulaziz University
    Inventors: Anwar M. Hashem, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Abdullah Algaissi, Khalid A. Alluhaybi
  • Prefusion coronavirus spike proteins and their use
    Patent number: 11964010
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 23, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • ENGINEERED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230242594
    Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Jason MCLELLAN, Jennifer MAYNARD, Andrea CHASSE, Ilya FINKELSTEIN, Mohammad JAVANMARDI, Jeffrey SCHAUB, Hung-Che KUO, Chia-Wei CHOU, Jory GOLDSMITH, Christy HJORTH, Ching-Lin HSIEH, Patrick BYRNE, Nicole JOHNSON, Nianshuang WANG, Daniel WRAPP
  • VACCINE BOOSTER COMPOSITIONS FOR RESPIRATORY VIRAL DISEASES
    Publication number: 20240024461
    Abstract: The present application provides chimeric proteins comprising comprising a receptor binding domain (“RBD”) of a SARS-CoV-2 spike protein (“S protein”) fused to a booster enhancer domain (“BED”) and uses thereof as vaccine or vaccine booster compositions. Also provided are method of boostering SARS-CoV-2 vaccines by administering to a vaccinated individual an effective amount of the vaccine booster composition, wherein the vaccine booster composition comprises a spike protein or a fragment thereof, and optionally wherein the vaccine booster composition is administered intranasally.
    Type: Application
    Filed: August 21, 2023
    Publication date: January 25, 2024
    Inventors: Kin Hang KOK, Kwok Yung YUEN, Joy Yan LAM
  • COMPOSITIONS AND USES OF SARS-COV-2 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED NK CELLS
    Publication number: 20230303654
    Abstract: Chimeric antigen receptors (CAR) targeted to SARS-CoV-2 Spike protein and NK cells expressing such CAR are described. The CAR are targeted to SARS-CoV-2 Spike protein via an scFv or a variant human ACE2 protein. In some cases, the NK cells also express human IL-15 or a soluble fragment thereof.
    Type: Application
    Filed: August 11, 2021
    Publication date: September 28, 2023
    Inventors: Jianhua Yu, Michael A. Caligiuri
  • Engineering, production and characterization of plant produced Nucleocapsid and Spike structural proteins of SARS CoV 2 as vaccine candidates against COVID19
    Publication number: 20230165951
    Abstract: This document relates to materials and methods for engineering and production of highly soluble, functional active recombinant Nucleocapsid (N) and Spike (S) based vaccine candidates against highly pandemic SARC-CoV-2 infection, in Nicotiana benthamiana plant using a transient expression system.
    Type: Application
    Filed: December 1, 2021
    Publication date: June 1, 2023
    Inventors: Tarlan Mamedov, Gulnara Hasanova
  • Sars coronavirus s proteins and uses thereof
    Publication number: 20070116716
    Abstract: The present invention relates to the use of a matured, glycosylated Spike (S) protein of SARS Coronavirus, fragments of the S protein, methods for producing the same, their use in detecting SARS infection, and their use or the use of their corresponding antibodies to treat patients suffering from SARS.
    Type: Application
    Filed: December 10, 2004
    Publication date: May 24, 2007
    Inventors: Shuo Shen, Wanjin Hong, Seng Lim, Yee Tan, Burtram Fielding, Phuay Goh, Timothy Tan, Jian Fu
  • BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES
    Publication number: 20230129210
    Abstract: Described herein are binding proteins useful against ACE2-targeted viruses (e.g., SARS-CoV and SARS-CoV-2, etc.), and methods of using them. These binding proteins may include an extracellular portion of angiotensin-converting enzyme 2 (ACE2), excluding the collectrin domain, and a flexible polypeptide flexible linker coupling the ACE2 portion to a fragment crystallization (Fc) domain. These binding proteins dimerize, and the flexible linker may be chosen to be sufficiently long to permit concurrent interaction with multiple Spike (S) proteins on the ACE2-targeted virus.
    Type: Application
    Filed: April 5, 2021
    Publication date: April 27, 2023
    Inventors: Samuel Lai, Karthik Tiruthani, Carlos Alberto Cruz Teran
  • SPECIFICITY ENHANCING REAGENTS FOR COVID-19 ANTIBODY TESTING
    Publication number: 20230168247
    Abstract: Methods of detecting SARS-CoV-2 antibodies with improved specificity are described. The methods can include contacting a sample potentially containing SARS-CoV-2 antibodies with a reagent to remove non-anti-SARS-CoV-2 antibodies, such as a reagent comprising an epitope from a nucleocapsid protein or spike protein of a common coronavirus. The methods can include contacting the sample with a mutant SARS-CoV-2 nucleocapsid protein or spike protein comprising a reduced number of common coronavirus epitopes. The methods can involve comparing results from an immunoassay performed with a SARS-CoV-2 protein to results obtained from immunoassays performed with analogous protein from one or more common coronaviruses.
    Type: Application
    Filed: April 26, 2021
    Publication date: June 1, 2023
    Applicant: University of Virginia Patent Foundation
    Inventors: James C. Zimring, Lindsay Ann Legendre Bazydlo, Joesph Richard Wiencek, James David Gorham, Heather Howie
  • Corona-virus-like particles comprising functionally deleted genomes
    Publication number: 20040071709
    Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutics, and vaccines derived thereof. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein wherein the methods include decreasing the contact between heptad repeat regions of the protein. The invention provides a peptide including a heptad repeat region of a corona viral spike protein and/or a functional fragment and/or an equivalent thereof. The invention also provides antibodies and inhibiting compounds.
    Type: Application
    Filed: April 14, 2003
    Publication date: April 15, 2004
    Inventors: Petrus Josephus Marie Rottier, Berend-Jan Bosch
  • COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUS
    Publication number: 20230263882
    Abstract: Disclosed herein are CpG-amphiphiles and corona virus antigens (e.g., a coronavirus spike protein, a peptide thereof, or a nucleic acid sequence encoding the same) for use in inducing an immune response in a subject, and methods of administering CpG-amphiphiles and coronavirus antigens (e.g., a coronavirus spike protein, a peptide thereof, a coronavirus nucleocapsid protein, a peptide thereof, or a nucleic acid sequence encoding the same) to induce an immune response in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 24, 2023
    Inventors: Martin P. STEINBUCK, Lochana M. SEENAPPA, Peter C. DEMUTH, Christopher M. HAQQ, Lisa MCNEIL
  • COMPOSITIONS AND METHODS FOR TARGETING CORONAVIRUS USING LIPID VESICLES INCLUDING EXOSOMES
    Publication number: 20230372468
    Abstract: The current disclosure provides compositions and methods for treatment and prevention of a coronavirus infection. Certain aspects are directed to lipid vesicles comprising SARS-CoV-2 spike protein or a portion or variant thereof. Further aspects include methods for treatment or prevention of a coronavirus infection comprising providing a lipid vesicle comprising a therapeutic protein, such as SARS-CoV-2 spike protein or ACE2. In some embodiments, the disclosed lipid vesicles are useful for targeted delivery of anti-viral therapeutic agents.
    Type: Application
    Filed: March 23, 2021
    Publication date: November 23, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventor: RAGHU KALLURI
  • Antibody-based blockage of SARS-CoV-2-specific furin cleavage site
    Publication number: 20220204590
    Abstract: The present invention provides an antibody and its use method for immunologically blocking furin cleavage site on the S1/S2 boundary of SARS-CoV-2 spike protein that are in purified form or from a biological sample to prevent the SARS-CoV-2 spike protein cleavage caused by furin and furin-related proteases.
    Type: Application
    Filed: December 30, 2020
    Publication date: June 30, 2022
    Inventors: Weiwei Li, Jessica Mliu Li, William Lei Lee
  • CORONAVIRUS VACCINE COMPRISING A MOSAIC PROTEIN
    Publication number: 20230256087
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Application
    Filed: January 19, 2023
    Publication date: August 17, 2023
    Inventor: Jorge E. OSORIO
  • IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
    Publication number: 20210275665
    Abstract: Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.
    Type: Application
    Filed: March 4, 2021
    Publication date: September 9, 2021
    Inventor: MICHAEL WAN CHO
  • METHODS, COMPOSITIONS, AND PROPHYLACTICS FOR TREATING, AMELIORATING, OR PREVENTING CORONAVIRUS DISEASE (COVID-19)
    Publication number: 20230235308
    Abstract: Disclosed are the methods and compositions for treating, ameliorating, or preventing COVID-19 or conditions associated with SARS-CoV-2 infection, and, also for reversing the damage caused by SARS-CoV-2 infection. Pharmaceutically acceptable compositions including spike protein binding partners, and optionally personal protective equipment included spike protein binding partners, are also disclosed.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 27, 2023
    Inventors: Matthew Pincus, Steven Evans, Fred Friedman
  • PAN-CORONAVIRUS VACCINE COMPOSITIONS
    Publication number: 20230226173
    Abstract: Pan-coronavirus recombinant vaccine compositions featuring whole proteins or sequences of proteins encompassing all mutations in variants of human and animal Coronaviruses (e.g., 36 mutations in spike protein) or a combination of mutated B cell epitopes, mutated combination of B cell epitopes, mutated CD4+ T cell epitopes, and mutated CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The mutated epitopes may comprise one or more mutations. The present invention also describes using several immuno-informatics and sequence alignment approaches to identify several human B cell, CD4+ and CD8+ T cell epitopes that are highly mutated. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of human and animal Coronaviruses mutations.
    Type: Application
    Filed: October 13, 2022
    Publication date: July 20, 2023
    Inventor: Lbachir BenMohamed
Narrow Results

Filter by US Classification